Editors' picks from other sources

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C news

Show

From To
New and experimental hepatitis C treatment
AbbVie Says It Can Be First With New Hepatitis C Drugs

AbbVie Inc. (ABBV) said it can win the race against Gilead Sciences Inc. (GILD) to bring to market a new generation of all-oral hepatitis C drugs.

Published
14 June 2013
From
Bloomberg
New and experimental hepatitis C treatment
FDA Grants Priority Review To Oral Hepatitis C Drug Sofosbuvir, Approval Set For December

Gilead's drug will be the first to hit the market in a new generation of targeted hepatitis C treatments with high cure rates.

Published
10 June 2013
From
Medical Daily
Hepatitis C symptoms and diagnosis
Blood tests OK for fibrosis diagnosis in hep C

Blood testing can accurately identify clinically significant fibrosis and cirrhosis in people with hepatitis C virus (HCV) infection and may be an alternative to liver biopsy in some patients, a new systematic review has found.

Published
05 June 2013
From
MedPage Today
New and experimental hepatitis C treatment
Drugs Go From Hit to Dud in Two Years in Hepatitis Race

The pace of innovation, spurred by drugmakers jostling for a slice of a market that may reach $15 billion by 2018, has turned hepatitis C research into one of the fastest-developing areas of medicine. That boosted Gilead’s shares to a record last month, and left others like Vertex facing dwindling sales as their products quickly go from revolutionary to outdated.

Published
04 June 2013
From
Bloomberg
Hepatitis C treatment
INCIVO® (telaprevir) Receives European Commission Approval for Twice Daily Dosing for Treatment of Genotype-1 Chronic Hepatitis C Virus (HCV)

Janssen Infectious Diseases-Diagnostics announced today that the European Commission has approved a new twice-daily dosing of INCIVO® (telaprevir), a direct-acting antiviral hepatitis C protease inhibitor, in combination with pegylated-interferon and ribavirin (PR) for naive and previous-treatment experienced patients.

Published
31 May 2013
From
PR Newswire
New and experimental hepatitis C treatment
An all-oral combination phase II study of Simeprevir and Samatasvir (IDX719) for the treatment of hepatitis C virus infection initiated

Medivir today announced that Idenix Pharmaceuticals Inc. has initiated a phase II clinical trial, called HELIX-1, evaluating an all-oral, direct-acting antiviral (DAA) HCV combination regimen of simeprevir, a once-daily protease inhibitor jointly developed by Medivir and Janssen R&D Ireland, and samatasvir (IDX719), Idenix’s once-daily pan-genotypic NS5A inhibitor.

Published
30 May 2013
From
Medivir
New and experimental hepatitis C treatment
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients

Janssen presented SVR12 results from the phase III PROMISE study of simeprevir in treatment-experienced genotype 1 chronic hepatitis C adult patients with compensated liver disease, including all stages of liver fibrosis, when administered once daily with pegylated interferon and ribavirin.

Published
22 May 2013
From
Janssen press release
Hepatitis C treatment
Recent Advances in the Treatment of Chronic Hepatitis C Threaten to Leave Some Parts of the World Behind

A scenario may develop where hepatitis C is largely eradicated from the developing world but exits in large pockets in developing countries.

Published
21 May 2013
From
Medscape (requires registration)
Hepatitis C symptoms and diagnosis
As Hepatitis C Spreads, Scotland Steps In

Scotland is ignoring conventional wisdom and making a bold push to control a virus that may be one of the biggest ticking time bombs in medicine.

Published
17 May 2013
From
Wall Street Journal
Hepatitis C symptoms and diagnosis
Viral Hepatitis. Are You At Risk?

Take this 5 minute Hepatitis Risk Assessment developed by the CDC and get a personalized report.

Published
15 May 2013
From
US CDC
← First12345...51Next →

Filter by country